Answer
Post-marketing reports with Increlex (mecasermin) included systemic hypersensitivity with anaphylaxis, generalized urticaria, angioedema and dyspnoea, with some patients requiring hospitalization.
Sources for this answer
- Increlex 10 mg/ml solution for injectionEsteve Pharmaceuticals (formerly Intrapharm Laboratories) · emc · SmPC §4.8 Undesirable effects · Version 2Document updated
Sources checked